Michal Tal, PhD (@ImmunoFever) header
Michal Tal, PhD (@ImmunoFever) profile picture

Immunoengineer @MITdeptofBE finding new ways to MEASURE and interpret #inflammation #SexDifferences #ChronicLyme #LongCOVID. Mom of 2. prev/ @Yale, @Stanford.

Massachusett land
Joined October 2016
Photo by Michal Tal, PhD (@ImmunoFever)Photo by Michal Tal, PhD (@ImmunoFever)Photo by Michal Tal, PhD (@ImmunoFever)Photo by Michal Tal, PhD (@ImmunoFever)Photo by Michal Tal, PhD (@ImmunoFever)Photo by Michal Tal, PhD (@ImmunoFever)Photo by Michal Tal, PhD (@ImmunoFever)Photo by Michal Tal, PhD (@ImmunoFever)Photo by Michal Tal, PhD (@ImmunoFever)Photo by Michal Tal, PhD (@ImmunoFever)
Finally online - sharing our findings that #Lyme disease bacteria can live in female reproductive organs for over a year and increase risk for gynecological disease!!! We found this increased risk in mice and humans! 😱 (thread below) medrxiv.org/content/10.1101/…
48
272
33
769
100,137
Michal Tal, PhD retweeted
Today's installment of MICROSCOPY: making the invisible visible since 1590! Watch the immune cells (white balls) zipping around until the blood pressure cuff gets to a high enough pressure to stop the flow, and how quickly they come back!
9
42
3
181
7,984
🫶 It was impressive enough to see the static photos we can take ourselves but to see the blood cells actually moving through the capillaries, and see what the BP cuff does and how it stops and distends the capillaries is really incredible. I’m excited for what you will discover!
3
11
306
Michal Tal, PhD retweeted
Very real, I took this video myself yesterday. And yes, you have red blood cells and white blood cells and your white blood cells are immune cells. The larger white balls you see there are granulocytes (neutrophils) and the smaller ones are lymphocytes (B cells, T cells)..
2
4
1
43
2,466
Michal Tal, PhD retweeted
I got tense just watching this! BP being taken. Squeeze (holds breath) and release (phew)
Today's installment of MICROSCOPY: making the invisible visible since 1590! Watch the immune cells (white balls) zipping around until the blood pressure cuff gets to a high enough pressure to stop the flow, and how quickly they come back!
2
7
512
Today's installment of MICROSCOPY: making the invisible visible since 1590! Watch the immune cells (white balls) zipping around until the blood pressure cuff gets to a high enough pressure to stop the flow, and how quickly they come back!
9
42
3
181
7,984
Michal Tal, PhD retweeted
Pulse pressure: what ageing reveals about our arteries Why does systolic blood pressure tend to rise with age while diastolic pressure may actually fall? The answer lies not simply in the heart, but in the progressive loss of elasticity of our arteries. Let's decipher it! Pulse pressure (PP) is the difference between systolic and diastolic blood pressure. That simple. For a blood pressure of 120/80 mmHg, PP is 40 mmHg. But what does this difference actually tell us? Each heartbeat ejects blood into the aorta, stretching its elastic walls. During diastole, the aorta recoils, maintaining blood flow even when the heart is relaxing. This is the Windkessel effect, which transforms intermittent cardiac ejection into relatively continuous peripheral blood flow. PP therefore depends primarily on two factors: - stroke volume and - arterial compliance. Greater stroke volume tends to increase PP, whereas greater arterial elasticity reduces it. What changes with age? As arteries age, elastin becomes fragmented, collagen contributes increasingly to wall stiffness, and advanced glycation end-products promote collagen cross-linking. The physiological consequences are particularly interesting. - Systolic pressure rises: a stiffer aorta expands less during ventricular ejection, producing a greater pressure increase. - Diastolic pressure may fall: reduced elastic recoil compromises the pressure maintained between heartbeats. - Pulse pressure widens: the difference between systolic and diastolic pressures increases. Furthermore, increased arterial stiffness accelerates pulse-wave propagation. Reflected pressure waves return earlier, often during systole rather than diastole, augmenting central systolic pressure. Why does this matter clinically? A widened pulse pressure increases left ventricular pulsatile afterload and is associated with cardiovascular risk, particularly in older adults. Meanwhile, reduced diastolic pressure may compromise coronary perfusion, especially in patients with coronary artery disease, because much of left ventricular myocardial perfusion occurs during diastole. Blood pressure is therefore more than two numbers: the distance between them reveals how effectively our arteries store and release the energy of each heartbeat.
1
12
21
872
Michal Tal, PhD retweeted
Replying to @ImmunoFever
I just made an account and voted This is what convinced me to do it: teapaw.org/ImmunoFever/status/211…
Replying to @ImmunoFever
What Is at Stake: The highest-voted project in this track wins a $5K People's Choice Prize, and the Federal Judging Panel evaluates both public votes and on-page comments when awarding up to $2.6 in Phase 2 MVP prizes (including the $1,000,000 Grand Prize and $500,000 Runner-Up)!
1
3
246
Please VOTE for MEASURE it to CURE it: AI Powered Clinical Innovation! The MAESTRO Health Innovators team has advanced to the FINAL phase of the HHS TOPx Tech Sprint, and the public now has an opportunity to support this work through the People's Choice vote. Studying the body's smallest blood vessels can help researchers better understand complex chronic illnesses? The MAESTRO Health Innovators team is developing an AI-powered approach to expand access to nailfold capillaroscopy, a noninvasive tool for examining small blood vessels. By collecting and analyzing data from more patients, the team aims to uncover biological abnormalities that could inform earlier diagnoses and more targeted treatments. Here's how: - Visit the project page below. - Register for a free account or sign in. - Click the thumbs-up button on the submission to cast your vote. Your vote is an opportunity to support researchers working to bring new tools, data, and scientific understanding to patients who urgently need better answers and treatments. Cast your vote: hubs.ly/Q04CBHf-0 #ComplexChronicIllness #ClinicalResearch #AIinHealthcare #PatientCenteredResearch
4
10
494
Michal Tal, PhD retweeted
Researchers at Pará State University studied 153 people with Long COVID and found links between muscle weakness, inflammation, iron regulation, and electrolytes. The findings suggest muscle dysfunction may involve more than muscle injury alone. mdpi.com/1999-4915/18/10/109…
5
30
3
89
4,063
Michal Tal, PhD retweeted
Today, in collaboration with Anthropic, we’re excited to share rapid initial progress towards an antibody treatment for food allergy, which affects over 200 million people worldwide, discovered with the help of Claude. At Divergence Labs, we believe that AI can unlock the next generation of antibody therapeutics with more effective mechanisms than before. Such mechanisms are urgently needed in food allergy, which involve overcoming one of the tightest affinity protein pairs in immunology, IgE and its receptor FcεRI, on mast cells. Treatment with Xolair—the only approved antibody for food allergy—sequesters circulating IgE, but mast cells remain sensitized for weeks to months due to the extraordinarily slow dissociation of IgE from FcεRI. We envision a treatment that actively pulls IgE off of FcεRI, without waiting for natural dissociation. Like picking a lock, this requires the right combination of geometry and force. Our research team, working with Claude, ideated on mechanisms to accomplish this disruption, and converged on an antibody format with two arms with different functions and epitopes. Within one month, we designed, synthesized, and experimentally confirmed the biophysical function of the two arms, which we are now assembling into full therapeutic formats.
133
632
130
5,139
502,366
For NAMs to take hold, Biology tenure practices in the US and Europe must evolve. They are too reliant on mice - individual investigators can run a lab supported by the huge infrastructure for mice, and be sole senior author, AS EXPECTED to get tenure. 🧵1/n
2
2
1
20
7,591
Michal Tal, PhD retweeted
Back in May I estimated 10,000 Ebola cases by August. They reported 10,000 cases today in mid October, so my estimate was either a month and a half off, or there’s some significant underreporting of cases. Probably a combination. Either way, this will very likely be biggest Ebola outbreak on record - nbcnews.com/world/africa/con…
Cases and deaths tripled in last week. The Ebola outbreak will grow exponentially until containment, roughly doubling every two weeks. Containment will take some months - we could have over 10,000 cases by August, and be the largest Ebola outbreak ever by the fall. “The outbreak is spreading rapidly, WHO leaders said, with almost 750 suspected cases and 177 suspected deaths, up from 246 cases and 65 deaths when it was first reported a week earlier.” theguardian.com/global-devel…
1
2
22
3,407
Michal Tal, PhD retweeted
🔬📈 We mapped #bioimage analysis use in #microscopy papers. ImageJ+Fiji dominate; others are rising. Papers undercite them and lack detail to reproduce analyses. By @T_Shakespeare & @Bruno_MSaraiva, with @inesmcunha, @caron_ajacobs & the Jacquemet lab 📄 doi.org/10.64898/2026.10.21.…
10
34
1,757
Michal Tal, PhD retweeted
Researchers in @ScienceAdvances have developed a multiplexed and implantable fiber sensor that monitors the bloodstream for real-time levels of sodium and potassium, two electrolytes that regulate important bodily functions like heart rhythm and fluid balance. scim.ag/4yyM9UE
3
18
100
19,434
Michal Tal, PhD retweeted
Eight years ago I had the idea of combining ustekinumab and vedolizumab after anti-TNF failure in Crohn's disease. Each drug alone only went so far. Would the two together do better? At UEG Week, Remo Panaccione presented the first data on ABBV-466, AbbVie's combination of risankizumab with trosunilimab, a new anti-α4β7 antibody. Trosunilimab isn't vedolizumab, and it isn't a biosimilar of it. It's a new human antibody that AbbVie first developed for HIV research. In their lab work it binds α4β7 about 13 times more tightly than a comparator built from published sequences. So α4β7 is back as a target in Crohn's disease, this time as a partner for IL-23 blockade. AbbVie's tissue data, not yet published, show why that might work. In CD tissue, the IL-23 receptor and α4β7 sit on mostly different cells. Risankizumab alone leaves most of the gut-homing cells untouched. The trial was part of the TARGET-CD platform study. It took 300 adults with moderate to severe CD, and three quarters had already failed an advanced therapy. They were randomised to risankizumab, trosunilimab or both (ABBV-466). Endoscopic remission at week 12 was 30% on the combination, against 21% and 18% on each drug alone. By week 24 it was 41% against 22% and 20%. The combination almost doubled the rate and was still climbing, while each drug alone had levelled off. By week 24, more than half on the combination had an endoscopic response. The pattern held in people who had already failed an advanced therapy: 40% against 21% and 13% at week 24. Early transcriptomics from small biopsy subsets look interesting too. Epithelial repair and barrier genes rose by week 12, and tissue repair, nerve growth and vitamin transport genes by week 24, mainly on the combination. Safety looked similar across the three arms. It's phase 2a and open-label. The only p-value is nominal, at week 24. Clinical remission wasn't presented, and the doses haven't been disclosed. But AbbVie is already running a blinded phase 2 platform study in around 2,000 people with CD and UC, which includes ABBV-466 at two doses. The harder test is under way. I should have run that study eight years ago. Of course, no one would have funded it back then!
1
25
77
6,123
Michal Tal, PhD retweeted
Preparing a long post on advanced combination therapy to cover the evidence, strategies, trials, commercial pressures and of course clinical need. It is a fascinating topic with lots to cover.
3
21
1,611
Michal Tal, PhD retweeted
Log in and vote for this if you have complex chronic illness (Long covid, ME/CFS, chrinic Lyme, etc)!
Help!!!! Any advice appreciated!!! We just lost our strong lead in the HHS TOPx voting and I want to get the word out about what we're trying to do and what a difference it makes to get objective measures! Any tips appreciated (also votes and comments)!!! invisibleillness.crowdicity.…
1
1
3
311
Michal Tal, PhD retweeted
"Measure it to CURE it" This is worth the energy expenditure. Sign up and Vote!! Patient diagnostics are one of the BIG missing pieces in chronic illness recovery. Objective diagnostic methods need to be cheap and home-based. I think the tech is already out there (with wearables) and techniques like capillaroscopy - but they need to be adequately studied. I am a big supporter of @ImmunoFever research and the MAESTRO team. Help her get to the top!
Help!!!! Any advice appreciated!!! We just lost our strong lead in the HHS TOPx voting and I want to get the word out about what we're trying to do and what a difference it makes to get objective measures! Any tips appreciated (also votes and comments)!!! invisibleillness.crowdicity.…
2
11
1
26
1,609
Help!!!! Any advice appreciated!!! We just lost our strong lead in the HHS TOPx voting and I want to get the word out about what we're trying to do and what a difference it makes to get objective measures! Any tips appreciated (also votes and comments)!!! invisibleillness.crowdicity.…
6
15
2
27
5,147